Menu Search
Equities

Insulet Corp

PODD:NSQ

Insulet Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)261.34
  • Today's Change-0.665 / -0.25%
  • Shares traded138.09k
  • 1 Year change+40.27%
  • Beta1.2014
Data delayed at least 15 minutes, as of Nov 22 2024 16:39 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy10
Outperform10
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 22 analysts offering 12 month price targets for Insulet Corp have a median target of 279.00, with a high estimate of 317.00 and a low estimate of 234.00. The median estimate represents a 6.49% increase from the last price of 262.00.
High21.0%317.00
Med6.5%279.00
Low-10.7%234.00

Earnings history & estimates in USD

On Nov 07, 2024, Insulet Corp reported 3rd quarter 2024 earnings of 0.90 per share. This result exceeded the 0.76 consensus of the 18 analysts covering the company and exceeded last year's 3rd quarter results by 26.76%.
The next earnings announcement is expected on Feb 20, 2025.
Average growth rate+22.08%
Insulet Corp reported annual 2023 earnings of 2.75 per share on Feb 22, 2024.
Average growth rate+160.20%
More ▼

Revenue history & estimates in USD

Insulet Corporation had 3rd quarter 2024 revenues of 543.90m. This bettered the 519.03m consensus of the 19 analysts covering the company. This was 51.88% above the prior year's 3rd quarter results.
Average growth rate+6.60%
Insulet Corporation had revenues for the full year 2023 of 1.70bn. This was 30.02% above the prior year's results.
Average growth rate+23.20%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.